The data are incrementally positive but from open-label extensions, not randomized controlled trials. The key catalysts are the Phase 3 ALKIVIA topline in Q3 2026 and UNITY in H2 2027. Traders should monitor for potential stock moves around those readouts. Near-term, the EULAR data alone are unlikely to drive sustained re-rating without confirmatory Phase 3 results.
Price Chart
Executive Summary
Argenx presented new long-term data for efgartigimod in myositis (ALKIVIA+ open-label extension) and Sjogren's disease (RHO+ extension) at EULAR 2026, showing sustained clinical benefit and consistent safety. Topline Phase 3 results for myositis (ALKIVIA) are expected in Q3 2026, and for Sjogren's (UNITY) in H2 2027. The data reinforce the FcRn mechanism in rheumatology but are interim open-label results, not pivotal.
Key Facts
- ALKIVIA+ myositis data at 52 weeks: 37.5% of continuous efgartigimod patients maintained major TIS improvement; mean TIS 52.19 for continuous arm, 49.62 for placebo-switch arm.
- RHO+ Sjogren's data at 72 weeks: median ClinESSDAI scores low at 2.5 (efgartigimod arm) and 2.0 (placebo-switch arm); maintenance of response on biweekly dosing.
- Cross-indication safety analysis: consistent profile across 834 treated patients and >1,300 patient-years of follow-up.
- Topline Phase 3 ALKIVIA (myositis) results expected Q3 2026; Phase 3 UNITY (Sjogren's) topline expected H2 2027.
- Phase 2 eSScape study design for systemic sclerosis presented; no data yet.
Financial Impact
No financial figures reported. Positive clinical data supports pipeline value for efgartigimod in two new indications (myositis, Sjogren's) with combined addressable market potentially in the billions, but no revenue or cost estimates provided.
Risk Factors
- Phase 3 ALKIVIA (myositis) may fail to meet primary endpoint despite Phase 2 signal.
- Phase 3 UNITY (Sjogren's) topline not expected until H2 2027; long wait with binary risk.
- Open-label extension data are subject to selection bias and lack placebo control.
- Competition from other FcRn blockers and alternative therapies in rheumatology.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-069786 |
| Document: tm2616678d1_6k.htm | 0001104659-26-069786 |
| Document: 0001104659-26-069786-index-headers.html | 0001104659-26-069786 |
| Document: 0001104659-26-069786-index.html | 0001104659-26-069786 |
| Document: 0001104659-26-069786.txt | 0001104659-26-069786 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Institutional Cluster | $984.04 $995.77 | ▲ +1.19% | ▲ +1.69% | $918.23 (−6.69%) |
Aug 17, 2026 6w ago | 6-K | $987.84 $1,011.11 | ▲ +2.36% | ▲ +3.55% | $918.23 (−7.05%) |
Aug 6, 2026 8w ago | Press Release | $875.30 $856.94 | ▼ −2.10% | ▼ −3.31% | $918.23 (+4.91%) |
Jul 27, 2026 9w ago | 6-K | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 27, 2026 9w ago | Press Release | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 23, 2026 10w ago | Press Release | $924.60 $872.58 | ▼ −5.63% | ▼ −6.10% | $918.23 (−0.69%) |
Jul 16, 2026 11w ago | Press Release | $857.97 $924.60 | ▲ +7.77% | ▲ +9.44% | $918.23 (+7.02%) |
Jun 23, 2026 14w ago | 6-K | $853.40 $912.46 | ▲ +6.92% | ▲ +5.91% | $918.23 (+7.60%) |
Jun 3, 2026 17w ago | 6-K | $813.14 $862.18 | ▲ +6.03% | ▲ +9.85% | $918.23 (+12.92%) |
May 8, 2026 20w ago | Press Release | $813.28 $776.26 | ▼ −4.55% | ▼ −4.47% | $918.23 (+12.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access